Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to verify the superiority of NIK-333 (Peretinoin) to placebo in
inhibiting the recurrence of HCV-positive HCC in patients showing complete cure of the
disease, with the recurrence-free survival as the primary endpoint, in a multi-center,
randomized, double-blind, placebo-controlled, parallel-group comparison study.